Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Нутритивная коррекция статуса обмена железа у женщин репродуктивного возраста: результаты открытого проспективного пострегистрационного исследования с активным контролем в параллельных группах - Научно-практический журнал Cardioсоматика Том 16, №1 (2025)
Нутритивная коррекция статуса обмена железа у женщин репродуктивного возраста: результаты открытого проспективного пострегистрационного исследования с активным контролем в параллельных группах
Бакиров Б.А., Нагаев И.Р., Донсков С.В. Нутритивная коррекция статуса обмена железа у женщин репродуктивного возраста: результаты открытого проспективного пострегистрационного исследования с активным контролем в параллельных группах // CardioСоматика. 2025. Т. 16, № 1. С. 62–75. DOI: 10.17816/CS677071 EDN: BYSQCJ
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обоснование. Железодефицитная анемия — одно из самых распространённых заболеваний в мире, которое стоит на первом месте по частоте встречаемости у женщин детородного возраста. Частота нежелательных явлений высока при приёме традиционных соединений железа. Необходим поиск новых соединений железа, обладающих лучшей переносимостью при сохранении параметров эффективности.
Цель. Сравнение результатов коррекции диеты у небеременных пациенток, которые получали бисглицинат железа, с результатами приёма сульфата железа.
Материалы и методы. В исследование были включены 120 женщин репродуктивного возраста (18–49 лет) с лёгкой степенью железодефицитной анемии, соответствующих критериям включения. Пациентки были рандомизированы на две группы. Пациентки основной группы получали исследуемый продукт, содержащий 30 мг элементарного железа в хелатной форме бисглицината в сочетании с витаминами С, В6, В12 и L-метилфолатом (БАД ВитаФерр), по 1 капсуле 1 раз в день во время еды. Пациентки контрольной группы получали препарат, содержащий 100 мг элементарного железа в виде сульфата в сочетании с 60 мг витамина С, по 2 таблетки в день. Общая длительность терапии составляла 60 дней.
Результаты. С корректировкой на исходный уровень гемоглобина в основной группе доля пациенток, достигших целевого уровня гемоглобина, составила 88,9%, в контрольной группе — 94,3% (p=0,240). В обеих группах статистически значимые межгрупповые различия в уровне гемоглобина, ферритина и сывороточного железа через 60 дней выявлены не были (р >0,05), что свидетельствует о равной эффективности применяемых схем. В исследовании установлено, что 30 мг бисглицината железа статистически значимо повышают уровень ферритина (с 24,1 до 32,3 нг/мл) с 15-го дня применения, а к 60-му дню средний уровень сывороточного ферритина составил 39,1 нг/мл (p <0,001). При оценке частоты возникновения нежелательных явлений была выявлена статистически значимая межгрупповая разница. Частота нежелательных явлений составила 16 (26,7%) в основной группе и 37 (61,7%) в контрольной группе (р <0,001).
Заключение. БАД ВитаФерр можно рассматривать как эффективное и безопасное средство для профилактики и лечения дефицита железа и анемии.
Ключевые слова: железодефицитная анемия, сульфат железа, бисглицинат железа
AIM: To compare the outcomes of dietary correction in nonpregnant women receiving iron bisglycinate vs those receiving iron sulfate.
MATERIALS AND METHODS: The study included 120 women of reproductive age (18–49 years) with mild iron deficiency anemia who met the inclusion criteria. Patients were randomized into 2 groups. The main group received the investigational product containing 30 mg of elemental iron in chelated bisglycinate form combined with vitamins C, B6, B12, and L-methylfolate (the dietary supplement VitaFerr), administered as 1 capsule once a day with food. The control group received a preparation containing 100 mg of elemental iron as sulfate combined with 60 mg of vitamin C, taken as 2 tablets per day. The total duration of therapy was 60 days.
RESULTS: After adjustment for baseline hemoglobin levels, the proportion of female patients who achieved the target hemoglobin level was 88.9% in the main group and 94.3% in the control group (p=0.240). No statistically significant between‑group differences were observed in hemoglobin, ferritin, or serum iron levels after 60 days (p >0.05), indicating comparable efficacy of the treatment regimens. The study showed that a daily dose of 30 mg of iron bisglycinate significantly increased serum ferritin levels — from 24.1 to 32.3 ng/mL by day 15, with a mean ferritin concentration of 39.1 ng/mL on day 60 (p <0.001). A statistically significant difference in the frequency of adverse events was observed between groups: 16 (26.7%) in the main group and 37 (61.7%) in the control group (p <0.001).
CONCLUSION: The dietary supplement VitaFerr may be considered an effective and safe option for the prevention and treatment of iron deficiency and anemia.
Keywords: iron deficiency anemia, iron sulfate, iron bisglycinate
Цель. Сравнение результатов коррекции диеты у небеременных пациенток, которые получали бисглицинат железа, с результатами приёма сульфата железа.
Материалы и методы. В исследование были включены 120 женщин репродуктивного возраста (18–49 лет) с лёгкой степенью железодефицитной анемии, соответствующих критериям включения. Пациентки были рандомизированы на две группы. Пациентки основной группы получали исследуемый продукт, содержащий 30 мг элементарного железа в хелатной форме бисглицината в сочетании с витаминами С, В6, В12 и L-метилфолатом (БАД ВитаФерр), по 1 капсуле 1 раз в день во время еды. Пациентки контрольной группы получали препарат, содержащий 100 мг элементарного железа в виде сульфата в сочетании с 60 мг витамина С, по 2 таблетки в день. Общая длительность терапии составляла 60 дней.
Результаты. С корректировкой на исходный уровень гемоглобина в основной группе доля пациенток, достигших целевого уровня гемоглобина, составила 88,9%, в контрольной группе — 94,3% (p=0,240). В обеих группах статистически значимые межгрупповые различия в уровне гемоглобина, ферритина и сывороточного железа через 60 дней выявлены не были (р >0,05), что свидетельствует о равной эффективности применяемых схем. В исследовании установлено, что 30 мг бисглицината железа статистически значимо повышают уровень ферритина (с 24,1 до 32,3 нг/мл) с 15-го дня применения, а к 60-му дню средний уровень сывороточного ферритина составил 39,1 нг/мл (p <0,001). При оценке частоты возникновения нежелательных явлений была выявлена статистически значимая межгрупповая разница. Частота нежелательных явлений составила 16 (26,7%) в основной группе и 37 (61,7%) в контрольной группе (р <0,001).
Заключение. БАД ВитаФерр можно рассматривать как эффективное и безопасное средство для профилактики и лечения дефицита железа и анемии.
Ключевые слова: железодефицитная анемия, сульфат железа, бисглицинат железа
________________________________________________
AIM: To compare the outcomes of dietary correction in nonpregnant women receiving iron bisglycinate vs those receiving iron sulfate.
MATERIALS AND METHODS: The study included 120 women of reproductive age (18–49 years) with mild iron deficiency anemia who met the inclusion criteria. Patients were randomized into 2 groups. The main group received the investigational product containing 30 mg of elemental iron in chelated bisglycinate form combined with vitamins C, B6, B12, and L-methylfolate (the dietary supplement VitaFerr), administered as 1 capsule once a day with food. The control group received a preparation containing 100 mg of elemental iron as sulfate combined with 60 mg of vitamin C, taken as 2 tablets per day. The total duration of therapy was 60 days.
RESULTS: After adjustment for baseline hemoglobin levels, the proportion of female patients who achieved the target hemoglobin level was 88.9% in the main group and 94.3% in the control group (p=0.240). No statistically significant between‑group differences were observed in hemoglobin, ferritin, or serum iron levels after 60 days (p >0.05), indicating comparable efficacy of the treatment regimens. The study showed that a daily dose of 30 mg of iron bisglycinate significantly increased serum ferritin levels — from 24.1 to 32.3 ng/mL by day 15, with a mean ferritin concentration of 39.1 ng/mL on day 60 (p <0.001). A statistically significant difference in the frequency of adverse events was observed between groups: 16 (26.7%) in the main group and 37 (61.7%) in the control group (p <0.001).
CONCLUSION: The dietary supplement VitaFerr may be considered an effective and safe option for the prevention and treatment of iron deficiency and anemia.
Keywords: iron deficiency anemia, iron sulfate, iron bisglycinate
Полный текст
Список литературы
1. Clinical recommendations of the Ministry of Health of the Russian Federation “Iron deficiency anemia”, 2024. Available from: https://cr.minzdrav.gov.ru/preview-cr/669_2
2. Camaschella C. Iron deficiency. Blood. 2019;133(1):30–9. doi: 10.1182/blood-2018-05-815944
3. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59. doi: 10.1016/S0140-6736(17)32154-2
4. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
5. Prevalence of anaemia in women of reproductive age (aged 15-49) (%). Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia-in-women-of...
6. Milman NT, Bergholt T. Low-Dose Prophylactic Oral Iron Supplementation (Ferrous Fumarate, Ferrous Bisglycinate, and Ferrous Sulphate) in Pregnancy Is Not Associated With Clinically Significant Gastrointestinal Complaints: Results From Two Randomized Studies. J Pregnancy. 2024;2024:1716798. doi: 10.1155/2024/1716798
7. Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435–43. doi: 10.1024/0300-9831.74.6.435
8. Liao Zh-Ch, Guan WT, Chen F, et al. Ferrous bisglycinate increased iron transportation through DMT1 and PepT1 in pig intestinal epithelial cells compared with ferrous sulphate. J Anim Feed Sci. 2014;23(2):153–159.
9. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381–4. doi: 10.1016/s0899-9007(01)00519-6
10. Ferrari P, Nicolini A, Manca ML, et al. Treatment of mild non‑chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedecine & pharmacotherapie. 2012;66(6):414–418. doi: 10.1016/j.biopha.2012.06.003
11. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta‑analysis of randomized controlled trials. Nutr Rev. 2023;81(8):904–920. doi: 10.1093/nutrit/nuac106
12. World Health Organization. (2017). Nutritional anaemias: tools for effective prevention and control. World Health Organization. 2017. Available from: https://apps.who.int/iris/handle/10665/259425. License: CC BY-NC-SA 3.0 IGO.
13. Russian Monitoring of the Economic Situation and Public Health at the Higher School of Economics (RLMS HSE), conducted by the National Research University Higher School of Economics and Demoscope LLC with the participation of the Population Center at the University of North Carolina at Chapel Hill and the Institute of Sociology at the Federal Research Sociological Center of the Russian Academy of Sciences. Survey sites RLMS HSE: http://www.hse.ru/rlms, https://rlms-hse.cpc.unc.edu
14. Piskin E, Cianciosi D, Gulec S, Tomas M, Capanoglu E. Iron Absorption: Factors, Limitations, and Improvement Methods. ACS Omega. 2022;7(24):20441–20456. doi: 10.1021/acsomega.2c01833
15. Giancotti L, Talarico V, Mazza GA, et al. Feralgine™ a new approach for iron deficiency anemia in celiac patients. Nutrients. 2019;11(4):887. doi: 10.3390/nu11040887
16. Mazza GA, Marrazzo S, Gangemi P, et al. Oral iron absorption test with ferrous bisglycinate chelate in children with celiac disease. Minerva Pediatr. 2019;71(2):139–143. doi: 10.23736/S0026-4946.16.04718-6
17. Szarfarc SC, de Cassana LM, Fujimori E, Guerra-Shinohara EM, de Oliveira IM. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women. Arch Latinoam Nutr. 2001;51(1 Suppl 1):42–47.
18. Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42(2):197–206. doi: 10.1515/jpm-2013-0153
19. Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR. Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Nutrients. 2022;14(3):452. doi: 10.3390/nu14030452
20. Abbas AM, Abdelbadee SA, Alanwar A, Mostafa S. Efficacy of ferrous bis‑glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial. J Matern Fetal Neonatal Med. 2019;32(24):4139–4145. doi: 10.1080/14767058.2018.1482871
21. Merrell BJ, McMurry JP. Folic Acid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
22. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014;44(5):480–8. doi: 10.3109/00498254.2013.845705
23. Sharma DC, Mathur R. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Indian J Physiol Pharmacol. 1995;39(4):403–406.
24. Chiamchanya N. Rapid recovery time of hemoglobin level in female regular blood donors with ferrous fumarate and high dose of ascorbic acid supplement. J Med Assoc Thai. 2013;96(2):165–171.
25. Mei Z, Serdula MK, Liu JM, et al. Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia. J Nutr. 2014;144(6):943–948. doi: 10.3945/jn.113.189894
26. Liu JM, Mei Z, Ye R, et al. Micronutrient supplementation and pregnancy outcomes: Double-blind randomized controlled trial in China. JAMA Intern Med. 2013;173(4):276–782. doi: 10.1001/jamainternmed.2013.1632
27. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2015;2015(11):CD004905. doi: 10.1002/14651858.CD004905.pub4
2. Camaschella C. Iron deficiency. Blood. 2019;133(1):30–9. doi: 10.1182/blood-2018-05-815944
3. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59. doi: 10.1016/S0140-6736(17)32154-2
4. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
5. Prevalence of anaemia in women of reproductive age (aged 15-49) (%). Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia-in-women-of...
6. Milman NT, Bergholt T. Low-Dose Prophylactic Oral Iron Supplementation (Ferrous Fumarate, Ferrous Bisglycinate, and Ferrous Sulphate) in Pregnancy Is Not Associated With Clinically Significant Gastrointestinal Complaints: Results From Two Randomized Studies. J Pregnancy. 2024;2024:1716798. doi: 10.1155/2024/1716798
7. Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435–43. doi: 10.1024/0300-9831.74.6.435
8. Liao Zh-Ch, Guan WT, Chen F, et al. Ferrous bisglycinate increased iron transportation through DMT1 and PepT1 in pig intestinal epithelial cells compared with ferrous sulphate. J Anim Feed Sci. 2014;23(2):153–159.
9. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381–4. doi: 10.1016/s0899-9007(01)00519-6
10. Ferrari P, Nicolini A, Manca ML, et al. Treatment of mild non‑chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedecine & pharmacotherapie. 2012;66(6):414–418. doi: 10.1016/j.biopha.2012.06.003
11. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta‑analysis of randomized controlled trials. Nutr Rev. 2023;81(8):904–920. doi: 10.1093/nutrit/nuac106
12. World Health Organization. (2017). Nutritional anaemias: tools for effective prevention and control. World Health Organization. 2017. Available from: https://apps.who.int/iris/handle/10665/259425. License: CC BY-NC-SA 3.0 IGO.
13. Russian Monitoring of the Economic Situation and Public Health at the Higher School of Economics (RLMS HSE), conducted by the National Research University Higher School of Economics and Demoscope LLC with the participation of the Population Center at the University of North Carolina at Chapel Hill and the Institute of Sociology at the Federal Research Sociological Center of the Russian Academy of Sciences. Survey sites RLMS HSE: http://www.hse.ru/rlms, https://rlms-hse.cpc.unc.edu
14. Piskin E, Cianciosi D, Gulec S, Tomas M, Capanoglu E. Iron Absorption: Factors, Limitations, and Improvement Methods. ACS Omega. 2022;7(24):20441–20456. doi: 10.1021/acsomega.2c01833
15. Giancotti L, Talarico V, Mazza GA, et al. Feralgine™ a new approach for iron deficiency anemia in celiac patients. Nutrients. 2019;11(4):887. doi: 10.3390/nu11040887
16. Mazza GA, Marrazzo S, Gangemi P, et al. Oral iron absorption test with ferrous bisglycinate chelate in children with celiac disease. Minerva Pediatr. 2019;71(2):139–143. doi: 10.23736/S0026-4946.16.04718-6
17. Szarfarc SC, de Cassana LM, Fujimori E, Guerra-Shinohara EM, de Oliveira IM. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women. Arch Latinoam Nutr. 2001;51(1 Suppl 1):42–47.
18. Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42(2):197–206. doi: 10.1515/jpm-2013-0153
19. Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR. Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Nutrients. 2022;14(3):452. doi: 10.3390/nu14030452
20. Abbas AM, Abdelbadee SA, Alanwar A, Mostafa S. Efficacy of ferrous bis‑glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial. J Matern Fetal Neonatal Med. 2019;32(24):4139–4145. doi: 10.1080/14767058.2018.1482871
21. Merrell BJ, McMurry JP. Folic Acid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
22. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014;44(5):480–8. doi: 10.3109/00498254.2013.845705
23. Sharma DC, Mathur R. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Indian J Physiol Pharmacol. 1995;39(4):403–406.
24. Chiamchanya N. Rapid recovery time of hemoglobin level in female regular blood donors with ferrous fumarate and high dose of ascorbic acid supplement. J Med Assoc Thai. 2013;96(2):165–171.
25. Mei Z, Serdula MK, Liu JM, et al. Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia. J Nutr. 2014;144(6):943–948. doi: 10.3945/jn.113.189894
26. Liu JM, Mei Z, Ye R, et al. Micronutrient supplementation and pregnancy outcomes: Double-blind randomized controlled trial in China. JAMA Intern Med. 2013;173(4):276–782. doi: 10.1001/jamainternmed.2013.1632
27. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2015;2015(11):CD004905. doi: 10.1002/14651858.CD004905.pub4
2. Camaschella C. Iron deficiency. Blood. 2019;133(1):30–9. doi: 10.1182/blood-2018-05-815944
3. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59. doi: 10.1016/S0140-6736(17)32154-2
4. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
5. Prevalence of anaemia in women of reproductive age (aged 15-49) (%). Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia-in-women-of...
6. Milman NT, Bergholt T. Low-Dose Prophylactic Oral Iron Supplementation (Ferrous Fumarate, Ferrous Bisglycinate, and Ferrous Sulphate) in Pregnancy Is Not Associated With Clinically Significant Gastrointestinal Complaints: Results From Two Randomized Studies. J Pregnancy. 2024;2024:1716798. doi: 10.1155/2024/1716798
7. Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435–43. doi: 10.1024/0300-9831.74.6.435
8. Liao Zh-Ch, Guan WT, Chen F, et al. Ferrous bisglycinate increased iron transportation through DMT1 and PepT1 in pig intestinal epithelial cells compared with ferrous sulphate. J Anim Feed Sci. 2014;23(2):153–159.
9. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381–4. doi: 10.1016/s0899-9007(01)00519-6
10. Ferrari P, Nicolini A, Manca ML, et al. Treatment of mild non‑chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedecine & pharmacotherapie. 2012;66(6):414–418. doi: 10.1016/j.biopha.2012.06.003
11. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta‑analysis of randomized controlled trials. Nutr Rev. 2023;81(8):904–920. doi: 10.1093/nutrit/nuac106
12. World Health Organization. (2017). Nutritional anaemias: tools for effective prevention and control. World Health Organization. 2017. Available from: https://apps.who.int/iris/handle/10665/259425. License: CC BY-NC-SA 3.0 IGO.
13. Russian Monitoring of the Economic Situation and Public Health at the Higher School of Economics (RLMS HSE), conducted by the National Research University Higher School of Economics and Demoscope LLC with the participation of the Population Center at the University of North Carolina at Chapel Hill and the Institute of Sociology at the Federal Research Sociological Center of the Russian Academy of Sciences. Survey sites RLMS HSE: http://www.hse.ru/rlms, https://rlms-hse.cpc.unc.edu
14. Piskin E, Cianciosi D, Gulec S, Tomas M, Capanoglu E. Iron Absorption: Factors, Limitations, and Improvement Methods. ACS Omega. 2022;7(24):20441–20456. doi: 10.1021/acsomega.2c01833
15. Giancotti L, Talarico V, Mazza GA, et al. Feralgine™ a new approach for iron deficiency anemia in celiac patients. Nutrients. 2019;11(4):887. doi: 10.3390/nu11040887
16. Mazza GA, Marrazzo S, Gangemi P, et al. Oral iron absorption test with ferrous bisglycinate chelate in children with celiac disease. Minerva Pediatr. 2019;71(2):139–143. doi: 10.23736/S0026-4946.16.04718-6
17. Szarfarc SC, de Cassana LM, Fujimori E, Guerra-Shinohara EM, de Oliveira IM. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women. Arch Latinoam Nutr. 2001;51(1 Suppl 1):42–47.
18. Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42(2):197–206. doi: 10.1515/jpm-2013-0153
19. Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR. Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Nutrients. 2022;14(3):452. doi: 10.3390/nu14030452
20. Abbas AM, Abdelbadee SA, Alanwar A, Mostafa S. Efficacy of ferrous bis‑glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial. J Matern Fetal Neonatal Med. 2019;32(24):4139–4145. doi: 10.1080/14767058.2018.1482871
21. Merrell BJ, McMurry JP. Folic Acid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
22. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014;44(5):480–8. doi: 10.3109/00498254.2013.845705
23. Sharma DC, Mathur R. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Indian J Physiol Pharmacol. 1995;39(4):403–406.
24. Chiamchanya N. Rapid recovery time of hemoglobin level in female regular blood donors with ferrous fumarate and high dose of ascorbic acid supplement. J Med Assoc Thai. 2013;96(2):165–171.
25. Mei Z, Serdula MK, Liu JM, et al. Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia. J Nutr. 2014;144(6):943–948. doi: 10.3945/jn.113.189894
26. Liu JM, Mei Z, Ye R, et al. Micronutrient supplementation and pregnancy outcomes: Double-blind randomized controlled trial in China. JAMA Intern Med. 2013;173(4):276–782. doi: 10.1001/jamainternmed.2013.1632
27. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2015;2015(11):CD004905. doi: 10.1002/14651858.CD004905.pub4
________________________________________________
2. Camaschella C. Iron deficiency. Blood. 2019;133(1):30–9. doi: 10.1182/blood-2018-05-815944
3. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59. doi: 10.1016/S0140-6736(17)32154-2
4. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
5. Prevalence of anaemia in women of reproductive age (aged 15-49) (%). Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia-in-women-of...
6. Milman NT, Bergholt T. Low-Dose Prophylactic Oral Iron Supplementation (Ferrous Fumarate, Ferrous Bisglycinate, and Ferrous Sulphate) in Pregnancy Is Not Associated With Clinically Significant Gastrointestinal Complaints: Results From Two Randomized Studies. J Pregnancy. 2024;2024:1716798. doi: 10.1155/2024/1716798
7. Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435–43. doi: 10.1024/0300-9831.74.6.435
8. Liao Zh-Ch, Guan WT, Chen F, et al. Ferrous bisglycinate increased iron transportation through DMT1 and PepT1 in pig intestinal epithelial cells compared with ferrous sulphate. J Anim Feed Sci. 2014;23(2):153–159.
9. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381–4. doi: 10.1016/s0899-9007(01)00519-6
10. Ferrari P, Nicolini A, Manca ML, et al. Treatment of mild non‑chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedecine & pharmacotherapie. 2012;66(6):414–418. doi: 10.1016/j.biopha.2012.06.003
11. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta‑analysis of randomized controlled trials. Nutr Rev. 2023;81(8):904–920. doi: 10.1093/nutrit/nuac106
12. World Health Organization. (2017). Nutritional anaemias: tools for effective prevention and control. World Health Organization. 2017. Available from: https://apps.who.int/iris/handle/10665/259425. License: CC BY-NC-SA 3.0 IGO.
13. Russian Monitoring of the Economic Situation and Public Health at the Higher School of Economics (RLMS HSE), conducted by the National Research University Higher School of Economics and Demoscope LLC with the participation of the Population Center at the University of North Carolina at Chapel Hill and the Institute of Sociology at the Federal Research Sociological Center of the Russian Academy of Sciences. Survey sites RLMS HSE: http://www.hse.ru/rlms, https://rlms-hse.cpc.unc.edu
14. Piskin E, Cianciosi D, Gulec S, Tomas M, Capanoglu E. Iron Absorption: Factors, Limitations, and Improvement Methods. ACS Omega. 2022;7(24):20441–20456. doi: 10.1021/acsomega.2c01833
15. Giancotti L, Talarico V, Mazza GA, et al. Feralgine™ a new approach for iron deficiency anemia in celiac patients. Nutrients. 2019;11(4):887. doi: 10.3390/nu11040887
16. Mazza GA, Marrazzo S, Gangemi P, et al. Oral iron absorption test with ferrous bisglycinate chelate in children with celiac disease. Minerva Pediatr. 2019;71(2):139–143. doi: 10.23736/S0026-4946.16.04718-6
17. Szarfarc SC, de Cassana LM, Fujimori E, Guerra-Shinohara EM, de Oliveira IM. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women. Arch Latinoam Nutr. 2001;51(1 Suppl 1):42–47.
18. Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42(2):197–206. doi: 10.1515/jpm-2013-0153
19. Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR. Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Nutrients. 2022;14(3):452. doi: 10.3390/nu14030452
20. Abbas AM, Abdelbadee SA, Alanwar A, Mostafa S. Efficacy of ferrous bis‑glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial. J Matern Fetal Neonatal Med. 2019;32(24):4139–4145. doi: 10.1080/14767058.2018.1482871
21. Merrell BJ, McMurry JP. Folic Acid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
22. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014;44(5):480–8. doi: 10.3109/00498254.2013.845705
23. Sharma DC, Mathur R. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Indian J Physiol Pharmacol. 1995;39(4):403–406.
24. Chiamchanya N. Rapid recovery time of hemoglobin level in female regular blood donors with ferrous fumarate and high dose of ascorbic acid supplement. J Med Assoc Thai. 2013;96(2):165–171.
25. Mei Z, Serdula MK, Liu JM, et al. Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia. J Nutr. 2014;144(6):943–948. doi: 10.3945/jn.113.189894
26. Liu JM, Mei Z, Ye R, et al. Micronutrient supplementation and pregnancy outcomes: Double-blind randomized controlled trial in China. JAMA Intern Med. 2013;173(4):276–782. doi: 10.1001/jamainternmed.2013.1632
27. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2015;2015(11):CD004905. doi: 10.1002/14651858.CD004905.pub4
Авторы
Б.А. Бакиров*1, И.Р. Нагаев1, С.В. Донсков2
1Башкирский государственный медицинский университет, Уфа, Россия;
2Петровакс Фарм, Москва, Россия
*bakirovb@gmail.com
1Bashkir State Medical University, Ufa, Russia;
2Petrovax Pharm, Moscow, Russia
*bakirovb@gmail.com
1Башкирский государственный медицинский университет, Уфа, Россия;
2Петровакс Фарм, Москва, Россия
*bakirovb@gmail.com
________________________________________________
1Bashkir State Medical University, Ufa, Russia;
2Petrovax Pharm, Moscow, Russia
*bakirovb@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.